MedDataX Logo

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

NCT ID: NCT04640480

Last Updated: 2023-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-21

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in participants with advanced solid tumors. Dose escalation will occur using a modified accelerated titration design (ATD).

All participants will receive SNB 101 in different cohorts. SNB 101 will be administered intravenously to participants on day 1 and day 15 of each 28 day treatment cycle until progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.

A Safety Review Committee will determine dose escalation, de-escalation, and modification and the MTD/RP2D based on DLTs and other safety information.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each participant will undergo a screening period, a treatment period, and a follow-up period. Participants will be followed until death, withdrawal of consent, or end of study, whichever occurs first.

During the treatment period, participants will receive SNB-101 (dose range: 5 mg/m2 to 50 mg/m2) intravenously on day 1 and day 15 of each 28 day cycle.

Dose reductions are permitted after the DLT observation period, which occurs during the first 28 days of treatment (cycle 1). Participants may permanently or temporarily (at the investigator's discretion) discontinue SNB-101. If a participant experiences a DLT or unacceptable toxicity, SNB-101 treatment should be interrupted until the observed toxicity returns to baseline or ≤ grade 1 toxicity. The start of the next cycle can be delayed up to 2 weeks at the investigator's discretion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Breast Cancer Pancreas Cancer Ovarian Cancer Small-cell Lung Cancer Gastric Cancer Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

1-7 cohorts, dose escalation method according to modified accelerated titration design
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

SNB-101 5/8mg/m2 Q2W IV

Group Type EXPERIMENTAL

SNB-101

Intervention Type DRUG

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Cohort 2

SNB-101 10/16mg/m2 Q2W IV

Group Type EXPERIMENTAL

SNB-101

Intervention Type DRUG

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Cohort 3

SNB-101 20/32mg/m2 Q2W IV

Group Type EXPERIMENTAL

SNB-101

Intervention Type DRUG

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Cohort 4

SNB-101 30/48mg/m2 Q2W IV

Group Type EXPERIMENTAL

SNB-101

Intervention Type DRUG

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Cohort 5

SNB-101 40/64mg/m2 Q2W IV

Group Type EXPERIMENTAL

SNB-101

Intervention Type DRUG

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Cohort 6

SNB-101 45/72mg/m2 Q2W IV

Group Type EXPERIMENTAL

SNB-101

Intervention Type DRUG

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Cohort 7

SNB-101 50/80mg/m2 Q2W IV

Group Type EXPERIMENTAL

SNB-101

Intervention Type DRUG

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SNB-101

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SN-38

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a histologically or cytologically confirmed, locally advanced or metastatic disease, has progressed after systemic standard of care treatment for advanced disease and is not suitable for complete surgical resection.
* Patients with measurable or evaluable disease consistent with Response Evaluation Criteria in Solid Tumors version 1.1.
* Patients ambulatory with an Eastern Cooperative Oncology Group performance score of 0 or 1.
* Patients with adequate hematological, renal, and liver function(CTCAE V5.0 grade 1 or lower).
* Patients with the life expectancy of 3 months or longer.

Exclusion Criteria

* Patients homozygous for UGT1A1\*28 or UGT1A1\*6 alleles.
* Patients known or suspected intolerance or hypersensitivity to main ingredient or any of the excipients of SNB-101.
* Patients with unintentional weight loss \>10% within 3 months prior to screening.
* Patients who are on dialysis.
* Patients who are positive for HIVs.
* Patients with a QT interval with Fridericia's correction outside of normal.
* Patients with intestinal palsy or bowel obstruction.
* Patients with chronic inflammatory bowel disease.
* Patients who may require administration of neuromuscular blockers, peripheral muscle relaxants, etc. during the study.
* Patients who may require lapatinib during the study.
* Patients who may require attenuated vaccine during the study.
* Patients who are taking any medication that in the judgement of the investigator could have an effect on the action of SNB-101.
* Patients unable to participate in the study as judged by the investigator.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SN BioScience

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joohang Kim, Dr

Role: STUDY_CHAIR

CHA Medical Center at Bundang

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHA Medical Center

Seongnam-si, Gyeonggi-do, South Korea

Site Status

The Severance Hospital of the Yonsei University

Seoul, , South Korea

Site Status

The Catholic University of Korea Seoul ST. Mary's Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jaehong Kim

Role: CONTACT

[email protected]
+82-31-757-3849

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Joohang Kim, Dr

Role: primary

Sunyoung Rha, Dr

Role: primary

Myung-ah Lee, Dr

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SNB-101-101

Identifier Type: -

Identifier Source: org_study_id